Compare Extra Space Storage, Inc. (EXR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Extra Space Storage, Inc. trades at $148.13 (market cap $30.56B), while Inovio Pharmaceuticals Inc trades at $1.16 (market cap $96.26M). The key difference: Extra Space Storage, Inc. is far larger — about 317.5× Inovio Pharmaceuticals Inc's market cap, and Extra Space Storage, Inc. pays a 4.48% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EXR | INO | |
|---|---|---|
Market Cap | $30.56B | $96.26M |
Sector | Real Estate | Health |
52-Week High | $152.75 | $2.87 |
52-Week Low | $126.67 | $1.05 |
Enterprise Value | $44.36B | $67.27M |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $145.50, showing modest daily gains of 0.12%. The stock exhibits neutral technical signals with support around $145 and resistance near $146. Fundamentally, the company maintains strong profitability with a 70.63% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights steady expansion and a new $550 million debt issuance at favorable rates, while analyst coverage shows a mixed consensus leaning toward Hold positions.
The outlook for EXR balances steady operational performance against valuation concerns. Investment opportunities include resilient self-storage demand, consistent dividend payments ($1.62 quarterly), and strategic acquisitions. Key risks involve elevated debt levels, new market supply pressures, and expense growth outpacing revenue. With a consensus price target of $155.88 suggesting 7% upside, the stock presents moderate growth potential tempered by sector headwinds.
INO trades at $1.16 with no recent price movement, reflecting its speculative biotech profile. The company shows consistent quarterly earnings beats but operates with minimal revenue ($65K in 2025) and significant losses (-$85M net income). Technical indicators are bearish overall, though some oscillators suggest potential oversold conditions. Recent news highlights the critical FDA decision for INO-3107 in October 2026 as the primary near-term catalyst.
The investment case hinges entirely on regulatory approval of INO-3107, with analysts maintaining a cautiously optimistic stance (53% buy ratings). However, substantial financial risks persist including negative cash flow, high burn rate, and shareholder litigation. Successful FDA approval could drive significant upside, while rejection would likely exacerbate financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
